Inve India ▾

Anuh Pharma share price & results

Anuh Pharma· Healthcare

Results to
Jun 2026
Ownership as of
Sept 2026

Tarapur-based manufacturer of Active Pharmaceutical Ingredients (bulk drugs) — erythromycin/macrolide salts, anti-TB, anti-malarial and corticosteroid APIs — for regulated export markets

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue194 ₹ crore+4.3% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin8.0 %+2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit11.0 ₹ crore+37.5% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity12.98 %−1.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-1.42 %−4.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)9.72 %+14.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Price

₹79.15 +2.71% · +₹2.09

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −8.9% 1Y

₹70.0₹80.0₹90.0Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹86.92 on 24 Oct 2025 → ₹79.15. High ₹96.74 (9 Sept 2026), low ₹67 (30 Mar 2026).

Previous close
₹77.06
Market cap
₹781 Cr
52-week range
₹67 – ₹96.74
One year
−11.52%
Price to earnings (TTM to Jun 2026)
17.75×
Return on equity (TTM to Jun 2026)
12.98%

Overview

Symbol
NSE:ANUHPHR
Exchange
NSE
Currency
INR

What Anuh Pharma does

Based on the company's own presentations, annual report and earnings calls.

Anuh Pharma manufactures Active Pharmaceutical Ingredients (bulk drugs) at a single EU-GMP/WHO-prequalified facility in Tarapur, Maharashtra, and is one of the largest producers of first-generation erythromycin (macrolide) salts and anti-TB APIs in India. It also makes anti-malarial, anti-diabetic, anti-bacterial, anti-histamine, anti-gout and corticosteroid APIs, supported by an in-house R&D facility at Mahape, Navi Mumbai. It earns by selling these APIs to pharmaceutical formulators and distributors both domestically and through export marketing partnerships across regulated and emerging markets.

Segments

  • Macrolides / Erythromycin salts
  • Anti-TB APIs
  • Anti-malarial APIs
  • Corticosteroids
  • Anti-diabetic APIs
  • Anti-bacterial / Antibiotic APIs
Manufacturing plants
1 facility at Tarapur, Maharashtra (11,400 sq. mtrs; 9 API blocks + 2 intermediate blocks)
Installed API capacity
2,400 MTPA (metric tons per annum)
Annual production volume
1,733 MT (FY26)
R&D facility
10,000 sq. ft. at Mahape, Navi Mumbai; 16 scientists
Export markets
72 countries (FY26)
Marketing partner customers
360 (FY26)
Founded 1960Headquarters Mumbai, Maharashtra, India Company website

Your own record

Start an Inve Case for Anuh Pharma

Free account: one company. Everything above stays public.

Write why you follow Anuh Pharma and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Anuh Pharma

Guides on how to read this kind of business and the numbers that matter.